Schmid, P., Sablin, M., Bergh, J., Im, S., Lu, Y., Martínez, N., . . . Cortés, J. (2021). A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Breast Cancer Res.
Chicago Stili AlıntıSchmid, Peter, et al. "A Phase Ib/II Study of Xentuzumab, an IGF-neutralising Antibody, Combined With Exemestane and Everolimus in Hormone Receptor-positive, HER2-negative Locally Advanced/metastatic Breast Cancer." Breast Cancer Res 2021.
MLA AlıntıSchmid, Peter, et al. "A Phase Ib/II Study of Xentuzumab, an IGF-neutralising Antibody, Combined With Exemestane and Everolimus in Hormone Receptor-positive, HER2-negative Locally Advanced/metastatic Breast Cancer." Breast Cancer Res 2021.